Publication details
Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma
| Title in English | Konsolidace léčby melfalanem 100 mg/m2 s novými léky pro pacienty s mnohočetným myelomem v náhlé progresi |
|---|---|
| Authors | |
| Year of publication | 2010 |
| Type | Article in Periodical |
| Magazine / Source | Annals of hematology |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | multiple myeloma; fuminant progression; melphalan |
| Description | Patients with fulminant progression of multiple myeloma after autologous stem cell transplantation (ASCT) have poor prognosis. Pancytopenia, extramedullary disease, and/or renal impairment are often present, and treatment options are limited. We have retrospectively evaluated 31 pts with FPG of MM after ASCT who were treated upfront salvage therapy with melphalan followed by PBSC support and consolidation therapy using regimens containing thalidomide or bortezomib.Treatment with upfront MEL 100 followed by a thalidomide or bortezomibbased regimen can prolong overall survival to more than 12 months in 33% of pts with fulminant progression of MM. |